GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB) » Definitions » Net Margin %

NUVB (Nuvation Bio) Net Margin % : -865.79% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Nuvation Bio Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Nuvation Bio's Net Income for the three months ended in Dec. 2024 was $-49.45 Mil. Nuvation Bio's Revenue for the three months ended in Dec. 2024 was $5.71 Mil. Therefore, Nuvation Bio's net margin for the quarter that ended in Dec. 2024 was -865.79%.

The historical rank and industry rank for Nuvation Bio's Net Margin % or its related term are showing as below:

NUVB' s Net Margin % Range Over the Past 10 Years
Min: -7213.76   Med: -7213.76   Max: -7213.76
Current: -7213.76


NUVB's Net Margin % is ranked worse than
90% of 1000 companies
in the Biotechnology industry
Industry Median: -126.84 vs NUVB: -7213.76

Nuvation Bio Net Margin % Historical Data

The historical data trend for Nuvation Bio's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvation Bio Net Margin % Chart

Nuvation Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Net Margin %
- - - - -7,213.76

Nuvation Bio Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -32,229.41 -5,668.50 -865.79

Competitive Comparison of Nuvation Bio's Net Margin %

For the Biotechnology subindustry, Nuvation Bio's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nuvation Bio's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuvation Bio's Net Margin % distribution charts can be found below:

* The bar in red indicates where Nuvation Bio's Net Margin % falls into.


;
;

Nuvation Bio Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Nuvation Bio's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin=Net Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-567.939/7.873
=-7,213.76 %

Nuvation Bio's Net Margin for the quarter that ended in Dec. 2024 is calculated as

Net Margin=Net Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-49.445/5.711
=-865.79 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nuvation Bio  (NYSE:NUVB) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Nuvation Bio Net Margin % Related Terms

Thank you for viewing the detailed overview of Nuvation Bio's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nuvation Bio Business Description

Traded in Other Exchanges
N/A
Address
1500 Broadway, Suite 1401, New York, NY, USA, 10036
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Executives
Kim D Blickenstaff director C/O MEDIVATION, INC., 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94105
Oleg Nodelman director 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Biotech Opportunity Gp, Llc director 1370 TRANCAS STREET, SUITE 176, NAPA CA 94558
Ecor1 Venture Opportunity Fund, Lp director 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital Fund, L.p. director 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital, Llc director 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital Fund Qualified, L.p. director 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Kathryn E Falberg director C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Dongfang Liu officer: Chief Medical Officer C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 401, NEW YORK NY 10036
Omega Fund V Gp, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund Iv Gp, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V Gp Manager, Ltd. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
David C. Hanley officer: Chief Technical Operations C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK NY 10036
Stacy Markel officer: SVP, Human Resources RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080